In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...

Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. LNZ100, an aceclidine-based eye drop, demonstrated a ...

For minor vision loss, simple adjustments like using brighter lights, wearing anti-glare sunglasses and using magnifiers can help. Changing the settings on your phone and computer to increase contrast ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.

Patients with presbyopia had consistent and durable vision improvement across multiple doses of a combination eye drop solution, a large retrospective review showed. From 69% to 99% of patients had ...